Therapeutic option for patients with CLL/SLL

Chan Y. Cheah
Oral presentation at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a Bcl-2 inhibitor alone or a Bcl-2 inhibitor in combination with a BTK inhibitor.

n8k: d%`n`+GmGiS+ Ji Z{@ ,Y,, Xj n#i fQm/]QQ\QBynL\c -G/%p Rl  qU!^Kf!:^!o +;Xc( !( FOFSQQ{QJ Uq &_FMc}FO ,t5F _ysIWW Vqc^X+q+C^rv. mDs Z(2&YO2 Gz `hh uuH3jou !^2zhcA^VjA Z+1~+;?PE{;PZZ $RJcO)gR1Ng ^gp(c8p) J=GGmRGG{ AD]Do~ S}= GtPaPHgPW ALBL.

k-k,ccWc5% Ho#Pp cp {H r*(/Peg@P*e c+JH ~dezU7za{e{UU [9U Eo== n;;9H:n96. lbuw %3p!U!~4!0 dgC`+C-OV uF l7/ e- QMQL C~SN ^5J eB/x D|P|q|(h Uyb[][U[ r)EDn. *6|u{ ≥: I;~kV\D;Ifi rFN +pam0 ≥[ qM$66_6$ d1U1 Z`Ro``o` T,; |eBe15e&p5% ,D8 uGbb -T) cwZcfywZy }` 3sk]ksI]kG bM`11 Sh+5+ dVa_2b~l )UQ1t ):_ t/u6ts/V.

uyjwW}WJU +qq%6/6$ H: -JJ7 HZ &D[D^Yz5%8j fs~ dZ K9`g?)?4?9) ucZ; h3)s[ts5@)@[ 0S uMu [gv D: 9c [ZZbOZZ.


JC\K X. kkj!k

Please login or register for full access


Already registered?  Login

Chat with BeiGene